State Street Corp Increases Position in Invivyd, Inc. (NASDAQ:IVVD)

State Street Corp lifted its holdings in Invivyd, Inc. (NASDAQ:IVVD) by 3.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,018,640 shares of the company’s stock after buying an additional 35,904 shares during the quarter. State Street Corp owned approximately 0.85% of Invivyd worth $1,039,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Proficio Capital Partners LLC bought a new position in Invivyd in the 3rd quarter valued at $27,000. XTX Topco Ltd grew its holdings in shares of Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new position in Invivyd in the 2nd quarter worth about $86,000. Rhumbline Advisers lifted its holdings in Invivyd by 4,434.1% during the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after buying an additional 82,164 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Invivyd in the 2nd quarter valued at about $115,000. 70.36% of the stock is owned by institutional investors.

Invivyd Trading Up 8.3 %

IVVD opened at $0.48 on Friday. The firm has a market cap of $57.42 million, a price-to-earnings ratio of -0.24 and a beta of 0.53. Invivyd, Inc. has a 12 month low of $0.40 and a 12 month high of $5.20. The stock has a fifty day moving average price of $0.70 and a 200-day moving average price of $0.95.

Insiders Place Their Bets

In other news, Director Terrance Mcguire sold 119,805 shares of Invivyd stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $0.42, for a total value of $50,318.10. Following the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at $1,498,675.08. The trade was a 3.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Morgan Stanley decreased their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. HC Wainwright lowered their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $7.89.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.